Vivos Inc Completes Certification Training Modules for Future IsoPet® Therapy Regional Clinics
Vivos Inc. (OTCQB: RDGL) has successfully developed nine certification training modules in collaboration with FX Masse, aimed at establishing regional clinics for IsoPet therapy. These modules, now available on the FX Masse website, facilitate a flexible learning environment for new clinics before hands-on training. The training process will be linked to handling licenses for radioactive materials. With the usage of innovative hydrogel technology, Vivos Inc. delivers targeted radiation therapy for tumors in both animals and humans, enhancing treatment safety and efficacy.
- Successful completion of nine certification training modules for IsoPet therapy.
- Training modules allow flexible learning for new clinics, optimizing resource use.
- Proprietary hydrogel technology enhances treatment safety and efficacy for tumors.
- None.
Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training for new regional clinics.
The modules are now on the FX Masse website with a separate unique UR web browser for Vivos Inc. This required a substantial investment in effort but the approach will be very cost effective. A new clinic can complete each module at their convenience as a pre-cursor to the hands-on certification training sessions. This certification will be linked to their radioactive material handling licenses.
Dr. Mike Korenko stated, “We were fortunate to team with this contractor to capitalize on their experience on producing these modules. They will also assist with the licensing. We needed to create an efficient and consistent process to initiate the establishment of regional clinics for IsoPet® therapy.”
About Vivos Inc. (OTCQB: RDGL)
Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
RadioGel™ also has a short half-life – delivering more than
The IsoPet® Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet® to University animal hospitals and private veterinary clinics.
IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
MKorenko@RadioGel.com
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
MKorenko@RadioGel.com
FAQ
What is the purpose of the training modules developed by Vivos Inc. (RDGL)?
How does Vivos Inc. (RDGL) ensure the safety of its radiation therapy?
What is IsoPet therapy offered by Vivos Inc. (RDGL)?
When was the PR released regarding Vivos Inc. (RDGL)'s training modules?
How does the new training process benefit Vivos Inc. (RDGL)?
